Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C

被引：1
作者：
Thibault A. [1 ,2 ]
Brissette S. [1 ,3 ]
Jutras-Aswad D. [1 ,2 ]
机构：
[1] Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 St-Denis Street, Montreal, H2X 0A9, QC
[2] Department of Psychiatry, Université de Montréal, Montreal
[3] Department of Family Medicine, Université de Montréal, Montreal
来源：
Addiction Science & Clinical Practice | / 10卷 / 1期
关键词：
Alcohol; Alcohol dependence; Baclofen; Disulfiram; Hepatitis C; Relapse prevention;
D O I：
10.1186/s13722-015-0029-2
中图分类号：
学科分类号：
摘要：
Treating alcohol use disorders (AUD) is critical in individuals suffering from hepatitis C infection (HCV). Aside from psychosocial interventions, pharmacological treatment is effective for decreasing alcohol consumption and promoting abstinence. However, unique factors belonging to HCV-infected individuals, such as baseline hepatic vulnerability and possible ongoing hepatitis C treatment, complicate AUD drug therapy. The goal of this review is to systematically identify, summarize, and evaluate the existing evidence on the pharmacological management of AUD in HCV-infected individuals. MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials were searched for English- and French-language articles published from 1993 to December 2013. The search criteria focused on clinical trials and observational studies assessing the efficacy and/or safety of pharmacological management of AUD in patients infected with HCV. Of 421 identified studies, three were included for analysis. Two were observational studies assessing the safety of disulfiram. One was a randomized controlled trial assessing the efficacy and safety of baclofen. There is paucity of data regarding the efficacy and safety of pharmacological treatment of AUD in HCV-infected individuals, with studies being small series and showing significant heterogeneity. No strong recommendations can be made based on the current studies as to which pharmacological option should be preferred in this sub-population. © 2015 Thibault et al.
引用
收藏
相关论文
共 57 条
  • [51] Butt A.A., Khan U.A., Shaikh O.S., McMahon D., Dorey-Stein Z., Tsevat J., Et al., Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers, HIV Clin Trials, 10, pp. 25-32, (2009)
  • [52] Rosner S., Hackl-Herrwerth A., Leucht S., Lehert P., Vecchi S., Soyka M., Acamprosate for alcohol dependence, Cochrane Database Syst Rev, 8, 9, (2010)
  • [53] Soyka M., Nalmefene for the treatment of alcohol dependence: A current update, Int J Neuropsychopharmacol, 17, pp. 675-684, (2014)
  • [54] Ahmed S.N., Siddiqi Z.A., Antiepileptic drugs and liver disease, Seizure, 15, pp. 156-164, (2006)
  • [55] Litwin A.H., Soloway I., Gourevitch M.N., Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities, Clinical Infect Dis, 40, pp. S339-S345, (2005)
  • [56] Sylvestre D.L., Zweben J.E., Integrating HCV services for drug users: A model to improve engagement and outcomes, Int J Drug Policy, 18, pp. 406-410, (2007)
  • [57] Proeschold-Bell R.J., Patkar A.A., Naggie S., Coward L., Mannelli P., Yao J., Et al., An integrated alcohol abuse and medical treatment model for patients with hepatitis C, Dig Dis Sci, 57, pp. 1083-1091, (2012)
123456